Jonathan Hansen, MD
Interventional Cardiology · Spokane, WANPI 1821432741
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $6,220 of the $10,280 with a category attached, or 60.5%. 10 manufacturers reported payments, led by Abbott at 27.3% of the total. Reporting peaked in 2024 at $4,410 and has fallen 84.7% since, to $674 in 2025.
Across 72 payments — averaging $142.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Ancora Heart, Inc.$3K
- Boston Scientific$2K
- Edwards Lifesciences$2K
- Medtronic$393
- Abiomed$138
- plus $185 from 4 others
Across 1 payment — averaging $9000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$9K
What the payments were for
- Travel & lodging$6,22061%
- Food & beverage$3,96139%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 23 | $2,802 |
| Ancora Heart, Inc. | 12 | $2,566 |
| Boston Scientific | 15 | $2,367 |
| Edwards Lifesciences | 11 | $1,828 |
| Medtronic(2 entities) | 5 | $393 |
| Abiomed | 1 | $138 |
| AstraZeneca | 2 | $113 |
| Endotronix, Inc. | 1 | $31 |
| Shockwave Medical, Inc | 1 | $21 |
| Asahi Intecc USA, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AccuCinch$2,310
- CROSSBOSS$1,921
- MitraClip$1,265
- Watchman$150
- Resolute$145
- Impella$138
- CoreValve Evolut$129
- GENERAL - STENTS$126
How this compares
$10,280 in reported general payments places this provider in the 65th percentile of 125 interventional cardiology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 113 | $127,194 |
| JardianceEmpagliflozin | 75 | $67,594 |
| EntrestoSacubitril/Valsartan | 24 | $23,725 |
| Repatha SureclickEvolocumab | 12 | $19,756 |
| Metoprolol Succinate | 224 | $3,256 |
| Ezetimibe | 72 | $2,640 |
| Rosuvastatin Calcium | 157 | $2,632 |
| ClopidogrelClopidogrel Bisulfate | 117 | $1,859 |
| Atorvastatin Calcium | 106 | $1,631 |
| Prasugrel Hcl | 37 | $1,413 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 91 | $1,136 |
| Torsemide | 50 | $912 |
| Losartan Potassium | 116 | $902 |
| Potassium Chloride | 53 | $818 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 27 | $705 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Spokane
- Mohit JainSpokane$98K
- Michael RingSpokane$47K
- Joel GallowaySpokane$12K
- Philip HuberSpokane$10K
- Dieter LubbeSpokane$7K
- Timothy BallSpokane$6K
- Brydan CurtisSpokane$5K
- William LombardiSeattle$902K
- Kathleen KearneySeattle$448K
- Robert RileyBellevue$431K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.